Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R

Respir Med. 2023 May:211:107216. doi: 10.1016/j.rmed.2023.107216. Epub 2023 Mar 21.
No abstract available

Keywords: Anti-IL5; Anti-IL5R; Asthma; Asthma remission; Benralizumab; Biologic treatment; FEOS score; Mepolizumab; Reslizumab; Super-responder.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Asthmatic Agents* / therapeutic use
  • Asthma* / drug therapy
  • Humans

Substances

  • Anti-Asthmatic Agents